Research Tools & Collaborations

Empowering Immunological Research - sTLR2 Tools and Collaboration Opportunities

IMIWN is committed to advancing the frontiers of immunology through advanced diagnostics and encouraging collaborative research. For immunologists, academic institutions, and pharmaceutical researchers, the sTLR2 RAPID Test and our expertise in soluble Toll-like Receptor 2 diagnostics, offer powerful tools and partnership opportunities to drive new discoveries in sepsis, inflammation, and innate immunity.

sTLR2 as a Versatile Research Tool

The sTLR2 RAPID Test is a robust research tool enabling immunologists to:

  • Investigate Innate Immune Signaling: Detect changes in sTLR2 levels to understand the dynamics of TLR2 activation and its modulation in various experimental models and human cohorts
  • Explore Host-Pathogen Interactions: Study how different pathogens or sterile insults elicit sTLR2 shedding and its impact on the host's inflammatory response
  • Characterise Inflammatory Phenotypes: Differentiate patient or model subgroups based on their sTLR2 profiles, leading to more nuanced understandings of disease heterogeneity
  • Screen and Validate Immunomodulators: Utilise sTLR2 as a sensitive biomarker to assess the biological activity of novel compounds designed to modulate immune responses
  • Conduct Longitudinal Studies: Monitor sTLR2 kinetics over time to track disease progression, treatment response, or long-term immunological consequences

Collaborate with IMIWN

We actively seek scientific collaborations to broaden the understanding and application of sTLR2 in diverse immunological contexts. Our team possesses expertise in immunoassay development and manufacture:

  • Access to Proprietary Technology: Collaborate using our sTLR2 RAPID Test, or enquire about access to our proprietary panel of sTLR2 monoclonal antibodies, polyclonal antibodies and sTLR2 monoclonal antibody pairs for specific research applications
  • Scientific Support: Benefit from our team's scientific knowledge in designing studies, interpreting results, and exploring new research avenues
  • Joint Research Initiatives: Partner on grants, publications, and clinical studies to accelerate discoveries in sepsis, inflammation, and related fields

Whether your research focuses on basic immunology, preclinical drug development, or translational studies, IMIWN can potentially help unlock the full potential of sTLR2 as a key immunological biomarker.

Contact us to discuss collaboration opportunities.